Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Masterful Antibodies: Checkpoint Blockade.

Nils Lonberg1, Alan J Korman2

  • 1Bristol-Myers Squibb, Biologics Discovery California, Redwood City, California. nils.lonberg@bms.com.

Cancer Immunology Research
|April 5, 2017
PubMed
Summary

Cancer immunotherapy, which harnesses the immune system to fight cancer, is increasingly vital. Early successes with drugs like ipilimumab and nivolumab highlight challenges and offer lessons for future cancer treatment advancements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Naturally self-reactive B cells are poised to cross the selection barrier into autoimmune germinal centers.

Cell reports·2026
Same author

Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling.

Science immunology·2026
Same author

Endothelial cells as targets of immune checkpoint blockade.

Journal for immunotherapy of cancer·2025
Same author

The Problem with Syngeneic Mouse Tumor Models.

Cancer immunology research·2025
Same author

Engineered ipilimumab variants that bind human and mouse CTLA-4.

mAbs·2025
Same author

A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression.

Scientific reports·2024

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Cancer immunotherapy represents a paradigm shift from traditional cancer cell-targeted therapies.
  • The significance of immune system-targeted drugs was underestimated until recently.
  • Early development focused heavily on cytotoxic agents targeting cancer cells directly.

Purpose of the Study:

  • To provide historical context on the discovery and development of early cancer immunotherapies.
  • To highlight the challenges encountered during the development of ipilimumab and nivolumab.
  • To offer insights for advancing future cancer immunotherapy research and patient treatment.

Main Methods:

  • Retrospective analysis of early-stage cancer immunotherapy development.
  • Case study approach focusing on ipilimumab and nivolumab.

Related Experiment Videos

  • Review of historical challenges in drug discovery and clinical translation.

    • Main Results:

    • Ipilimumab and nivolumab emerged as pioneering immune system-targeted cancer therapeutics.
    • The development journey revealed significant scientific and clinical hurdles.
    • These early successes paved the way for broader adoption of immunotherapy.

    Conclusions:

    • Cancer immunotherapy is now a standard of care for numerous malignancies.
    • Understanding the historical challenges is crucial for optimizing future immunotherapy development.
    • Continued innovation in targeting the immune system promises greater patient benefit.